Extrapyramidal symptoms (EPS) are a group of movement disturbances that arise when the brain's motor control systems are disrupted. They are characterized by involuntary or abnormal movements, altered muscle tone, and difficulties initiating or controlling voluntary movement. EPS most commonly result from interference with neurotransmitter systems in the basal ganglia but can also be seen in a variety of neurological diseases and after head trauma.
Common signs and patterns
- Dystonia: sudden, sustained muscle contractions causing twisting or abnormal postures, often affecting the neck, face or eyes.
- Parkinsonism: slowed movement (bradykinesia), rigidity, tremor and a shuffling gait resembling Parkinson's disease.
- Akathisia: a distressing inner restlessness with an urge to move that can cause pacing or inability to sit still.
- Tardive dyskinesia: repetitive, involuntary movements (lip smacking, tongue protrusion, blinking) that usually appear after long-term exposure to certain drugs.
Symptoms can range from mild and transient to severe and persistent. Affected regions are frequently the face, neck and limbs; speech and swallowing may be disturbed in some cases. For patient guidance and support resources see patient information.
Causes and mechanism
EPS most often stem from altered regulation of dopamine and its interaction with other neurotransmitters in the basal ganglia. Many widely used drugs can precipitate these effects—particularly some antipsychotic medications and certain antiemetics—so medication history is central to assessment. See also information on common offending medicines. Non-drug causes include neurodegenerative conditions such as Parkinson's disease, structural brain injury and metabolic or infectious processes that affect motor pathways.
Evaluation and management
Diagnosis is primarily clinical, based on symptom pattern and timing relative to exposures. Evaluation usually involves a review of current and past medications, a neurological examination, and sometimes laboratory tests or imaging to rule out other causes. Short-term or acute reactions may respond to prompt changes in medication, temporary use of anticholinergic agents or benzodiazepines, and supportive care. Longer-term or tardive syndromes may require specialist review and consideration of switching to lower-risk therapies, gradual dose reduction, or treatments specifically approved for tardive dyskinesia.
Prognosis varies: acute drug-induced EPS often improve after adjusting therapy, while tardive manifestations can be persistent or irreversible. Early recognition and liaison between prescribing clinicians and neurologists reduce disability and improve outcomes. Distinguishing EPS from primary movement disorders is important for appropriate treatment and counseling about risks and expected course.